A phosphorylation switch controls androgen biosynthesis in prostate cancer
Androgen biosynthesis enzyme 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1) encoded by HSD3B1 has emerged as a potential driver for therapeutic resistance in prostate cancer. Patients with homozygous HSD3B1(1245C) inheritance are intrinsically more resistant to currently available androgen/androgen...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical Investigation
2023-01-01
|
Series: | The Journal of Clinical Investigation |
Online Access: | https://doi.org/10.1172/JCI166499 |